Furthermore, the extended half-life of up to 8.7 h allows for the recommended once-daily dosing in most infections and populations, including critically ill patients [94,95,96,97] However, there is concern for achieving and maintaining adequate pharmacodynamic targets using once-daily dosing in critically ill patients, especially those with low serum albumin, due to increased renal clearance and volume of distribution in this highly protein-bound drug (83–96%) [95,96]. The gene discussed is ALB; the disease is infection.